Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer
- PMID: 17503156
- DOI: 10.1245/s10434-007-9410-z
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer
Abstract
Background: The aim of this study was to analyze the anatomic distribution, timing, and outcomes of recurrent disease after complete cytoreduction and perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis of colorectal origin.
Methods: Data regarding all patients who underwent complete cytoreduction and PIC for carcinomatosis from colorectal cancer were extracted from a prospectively collected database. The information regarding recurrent disease found on diagnostic evaluation and/or abdominal exploration was analyzed.
Results: Seventy patients underwent complete cytoreduction and perioperative intraperitoneal chemotherapy, and 49 of them had documented recurrent disease. The median time to progression for these 49 patients was 9 months while their median survival was 30 months. Eighteen patients had a localized intra-abdominal recurrence, 10 had diffuse intraperitoneal recurrence, 10 had isolated distant metastases, and 11 had a combination of distant metastases and intra-abdominal recurrence. There was a statistically significant difference in survival for patients with different patterns of recurrence (P = .012). Twenty-six patients underwent a second operation. The median survival of these patients was significantly longer than that of patients who did not have a second operation (39 vs 20 months, P = .0003). Four of the 49 patients with recurrences were still alive at the time of last follow-up, and three of them have no evidence of disease 73, 96, and 206 months after the diagnosis of recurrence.
Conclusions: Recurrence is a frequent event after optimal cytoreduction and PIC for carcinomatosis from colorectal cancer. Surgical treatment for a selected group of patients with recurrent disease may result in long-term survival.
Comment in
-
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal carcinomatosis: if at first you don't succeed...Ann Surg Oncol. 2007 Nov;14(11):3037-9. doi: 10.1245/s10434-007-9548-8. Epub 2007 Aug 29. Ann Surg Oncol. 2007. PMID: 17726635 No abstract available.
Similar articles
-
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.Ann Surg Oncol. 2007 Aug;14(8):2289-99. doi: 10.1245/s10434-007-9462-0. Epub 2007 Jun 1. Ann Surg Oncol. 2007. PMID: 17541772
-
Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.Ann Surg Oncol. 2004 Apr;11(4):375-9. doi: 10.1245/ASO.2004.08.014. Epub 2004 Mar 15. Ann Surg Oncol. 2004. PMID: 15070596 Clinical Trial.
-
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.Ann Surg Oncol. 2008 Sep;15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3. Ann Surg Oncol. 2008. PMID: 18521686 Clinical Trial.
-
[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].Minerva Chir. 2002 Oct;57(5):597-605. Minerva Chir. 2002. PMID: 12370661 Review. Italian.
-
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed].Bull Cancer. 2005 Feb;92(2):151-4. Bull Cancer. 2005. PMID: 15749644 Review. French.
Cited by
-
Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy.Drug Deliv. 2019 Dec;26(1):898-917. doi: 10.1080/10717544.2019.1660435. Drug Deliv. 2019. PMID: 31526065 Free PMC article.
-
Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients.Gastroenterol Res Pract. 2012;2012:827534. doi: 10.1155/2012/827534. Epub 2012 Jul 3. Gastroenterol Res Pract. 2012. PMID: 22811702 Free PMC article.
-
Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary?J Oncol. 2014;2014:307317. doi: 10.1155/2014/307317. Epub 2014 Apr 22. J Oncol. 2014. PMID: 24864143 Free PMC article.
-
Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy.Clin Colon Rectal Surg. 2015 Dec;28(4):234-46. doi: 10.1055/s-0035-1564431. Clin Colon Rectal Surg. 2015. PMID: 26648794 Free PMC article. Review.
-
Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.Langenbecks Arch Surg. 2019 Aug;404(5):527-539. doi: 10.1007/s00423-019-01805-x. Epub 2019 Aug 3. Langenbecks Arch Surg. 2019. PMID: 31377856
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical